Revelation Biosciences Inc Ordinary Shares REVB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if REVB is a good fit for your portfolio.
News
-
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
-
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
-
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
-
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
-
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
-
Thinking about buying stock in Meta Platforms, Ocular Therapeutix, Phathom Pharmaceuticals, Revelation Biosciences, or Sunworks?
-
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
-
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
Trading Information
- Previous Close Price
- $2.14
- Day Range
- $2.12–2.31
- 52-Week Range
- $1.78–39.00
- Bid/Ask
- $2.06 / $2.18
- Market Cap
- $3.56 Mil
- Volume/Avg
- 45,621 / 283,258
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body’s innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 9
- Website
- https://www.revbiosciences.com
Valuation
|
Metric
|
REVB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.09 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
REVB
Financial Strength
|
Metric
|
REVB
|
|---|---|
Quick Ratio | 2.15 |
Current Ratio | 2.18 |
Interest Coverage | — |
Quick Ratio
REVB
Profitability
|
Metric
|
REVB
|
|---|---|
Return on Assets (Normalized) | −62.74% |
Return on Equity (Normalized) | −109.27% |
Return on Invested Capital (Normalized) | −109.27% |
Return on Assets
REVB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zgzbpvhdm | Qrqzm | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pbxnqrx | Yfscjc | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dlgwlmm | Zxmfgsg | $97.8 Bil | |
MRNA
| Moderna Inc | Lfsbzhvp | Qgzx | $41.3 Bil | |
ARGX
| argenx SE ADR | Lbsxnjtd | Xhsc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Vgwbnllp | Hkf | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gkxhknkl | Sbglhq | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zwscgwmw | Jmsqtxw | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kfpftfhpy | Yfbst | $12.5 Bil | |
INCY
| Incyte Corp | Chqpcfrm | Pvfdpnq | $11.6 Bil |